Hicks DG - Search Results

1

A novel detection methodology for HER2 protein quantitation in formalin-fixed, paraffin embedded clinical samples using fluorescent nanoparticles: an analytical and clinical validation study.

Hicks DG, Buscaglia B, Goda H, McMahon L, Natori T, Turner B, Soukiazian A, Okada H, Nakano Y. Hicks DG, et al. BMC Cancer. 2018 Dec 18;18(1):1266. doi: 10.1186/s12885-018-5172-1. BMC Cancer. 2018. PMID: 30563489 Free PMC article.

2

HER2-Low Breast Cancers.

Zhang H, Katerji H, Turner BM, Hicks DG. Zhang H, et al. Among authors: hicks dg. Am J Clin Pathol. 2022 Mar 3;157(3):328-336. doi: 10.1093/ajcp/aqab117. Am J Clin Pathol. 2022. PMID: 34519765 Review.

3

The value of algorithms predicting the Oncotype DX recurrence score should not be underestimated!

Turner B, Tang P, Hicks D. Turner B, et al. Breast Cancer Res Treat. 2017 Jul;164(1):249-250. doi: 10.1007/s10549-017-4236-2. Epub 2017 Apr 13. Breast Cancer Res Treat. 2017. PMID: 28409240 No abstract available.

4

Impact of Specimen Type and Specimen Number on HER2 Status in Gastroesophageal Junction and Gastric Adenocarcinoma.

Huber AR, Buscaglia B, Koltz BR, Henry J, McMahon L, Guo J, Hicks DG, Whitney-Miller CL. Huber AR, et al. Among authors: hicks dg. Am J Clin Pathol. 2019 Apr 2;151(5):461-468. doi: 10.1093/ajcp/aqy166. Am J Clin Pathol. 2019. PMID: 30624589

5

Reconsidering "low-risk" criteria for breast cancer recurrence in hormone positive patients.

Soukiazian A, Hicks DG, Turner BM. Soukiazian A, et al. Among authors: hicks dg. Breast J. 2019 May;25(3):545-547. doi: 10.1111/tbj.13275. Epub 2019 Apr 10. Breast J. 2019. PMID: 30972823 No abstract available.

6

Applying the New Guidelines of HER2 Testing in Breast Cancer.

Zhang H, Moisini I, Ajabnoor RM, Turner BM, Hicks DG. Zhang H, et al. Among authors: hicks dg. Curr Oncol Rep. 2020 Apr 29;22(5):51. doi: 10.1007/s11912-020-0901-4. Curr Oncol Rep. 2020. PMID: 32346807 Review.

7

Significance of HER2 in Microinvasive Breast Carcinoma.

Zhang H, Moisini I, Turner BM, Wang X, Dhakal A, Yang Q, Kovar S, Schiffhauer LM, Hicks DG. Zhang H, et al. Among authors: hicks dg. Am J Clin Pathol. 2021 Jun 17;156(1):155-165. doi: 10.1093/ajcp/aqaa222. Am J Clin Pathol. 2021. PMID: 33491064

8

L1CAM Expression in Recurrent Estrogen Positive/HER2 Negative Breast Cancer: A Novel Biomarker Worth Considering.

Moisini I, Zhang H, D'Aguiar M, Hicks DG, Turner BM. Moisini I, et al. Among authors: hicks dg. Appl Immunohistochem Mol Morphol. 2021 Apr 1;29(4):287-292. doi: 10.1097/PAI.0000000000000909. Appl Immunohistochem Mol Morphol. 2021. PMID: 33818537

9

HER2-low breast cancers: incidence, HER2 staining patterns, clinicopathologic features, MammaPrint and BluePrint genomic profiles.

Zhang H, Katerji H, Turner BM, Audeh W, Hicks DG. Zhang H, et al. Among authors: hicks dg. Mod Pathol. 2022 Aug;35(8):1075-1082. doi: 10.1038/s41379-022-01019-5. Epub 2022 Feb 19. Mod Pathol. 2022. PMID: 35184150 Free article.

10

A lower Allred score for progesterone receptor is strongly associated with a higher recurrence score of 21-gene assay in breast cancer.

Tang P, Wang J, Hicks DG, Wang X, Schiffhauer L, McMahon L, Yang Q, Shayne M, Huston A, Skinner KA, Griggs J, Lyman G. Tang P, et al. Among authors: hicks dg. Cancer Invest. 2010 Nov;28(9):978-82. doi: 10.3109/07357907.2010.496754. Cancer Invest. 2010. PMID: 20690804

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

373 results

Search Page

Filters